PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
231.81%
G&A change of 231.81% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
-559.42%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
182.89%
Operating expenses change of 182.89% versus flat Biotechnology costs. Walter Schloss would verify control.
182.89%
Total costs change of 182.89% versus flat Biotechnology costs. Walter Schloss would verify control.
10.64%
Interest expense change of 10.64% versus flat Biotechnology costs. Walter Schloss would verify control.
No Data
No Data available this quarter, please select a different quarter.
-245.34%
EBITDA decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-249.64%
Operating income decline while Biotechnology median is -3.56%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56.01%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-146.74%
Net income decline while Biotechnology median is -0.12%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-145.19%
EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
-145.19%
Diluted EPS decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.